Literature DB >> 10744934

Is dissection of the internerve tissue during axillary lymphadenectomy for breast cancer necessary?

A Mostafa1, K Mokbel, A Engledow, A C Leris, C Choy, C Wells, R Carpenter.   

Abstract

AIMS: The study evaluates the necessity of dissecting the tissue between the long thoracic and thoracodorsal nerves (internerve tissue) during axillary dissection in breast cancer surgery. By reviewing the lymph node yield and the metastatic rate in the internerve tissue, we examine whether the internerve tissue could be left in situ to minimize the risk of nerve injury.
METHODS: A prospective study was conducted on 30 consecutive women undergoing axillary lymphadenectomy for breast cancer. The internerve tissue remaining was excised separately after a routine axillary dissection and was examined by the same pathologist.
RESULTS: Twenty (67%) of 30 internerve specimens contained lymph nodes; the internerve nodes were positive for carcinoma in three cases (10%). In one case the lymph node in the internerve tissue was the only metastatic node in the axilla.
CONCLUSIONS: There is a significant incidence of lymph nodes (67%) and axillary node metastases (10%) in the tissue lying between the long thoracic and thoracodorsal nerves. Therefore excision of this internerve tissue is strongly recommended in order to optimize decision making regarding adjuvant treatment and oucome in women with operable breast cancer. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10744934     DOI: 10.1053/ejso.1999.0760

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  1 in total

1.  Scapula alata in early breast cancer patients enrolled in a randomized clinical trial of post-surgery short-course image-guided radiotherapy.

Authors:  Nele Adriaenssens; Mark De Ridder; Pierre Lievens; Hilde Van Parijs; Marian Vanhoeij; Geertje Miedema; Mia Voordeckers; Harijati Versmessen; Guy Storme; Jan Lamote; Stephanie Pauwels; Vincent Vinh-Hung
Journal:  World J Surg Oncol       Date:  2012-05-16       Impact factor: 2.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.